Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, announced that CEO Markus Warmuth will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 3:30 p.m. ET. The presentation will be webcast live on Monte Rosa's website and archived for 30 days.
- Monte Rosa's participation in a high-profile event like the Jefferies Global Healthcare Conference increases visibility.
- The webcast availability provides potential investors and stakeholders easy access to company information.
- No new financial or clinical data was revealed in the announcement.
- The press release lacks substantive updates on business developments or clinical trial progress.
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 3:30 p.m. ET.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
What will Monte Rosa Therapeutics present at the Jefferies Global Healthcare Conference?
When is Monte Rosa Therapeutics presenting at the Jefferies Global Healthcare Conference?
How can I watch Monte Rosa Therapeutics' presentation at the Jefferies Global Healthcare Conference?
What is the stock symbol for Monte Rosa Therapeutics?
